Dayvigo Cardiovascular Impact Long-Term: What the Evidence Shows

Why Cardiovascular Safety Matters for Insomnia Drugs

Insomnia affects roughly 30% of adults in the United States, and a large proportion of those patients carry at least one cardiovascular comorbidity. Sleep itself modulates blood pressure dipping, sympathetic tone, and inflammatory pathways. Drugs that perturb sleep architecture, autonomic signaling, or cardiac ion channels in this population can shift risk in ways that do not appear in short-term efficacy trials.

Older pharmacological options illustrate the problem clearly. Benzodiazepines and Z-drugs are associated with nocturnal hypotension and falls in older adults. Tricyclic sedatives like doxepin carry QTc-prolongation risk at higher doses. Even diphenhydramine can raise resting heart rate through anticholinergic effects. Against that backdrop, the dual orexin receptor antagonist (DORA) class, which includes suvorexant (Belsomra) and lemborexant (Dayvigo), was positioned partly on the promise of a cleaner autonomic profile.

Understanding exactly what the data support, and where genuine gaps remain, requires a close look at the full lemborexant trial program rather than headline efficacy figures alone.

The Orexin System and the Heart

Orexin-A and orexin-B neuropeptides are produced in the lateral hypothalamus and project widely to brainstem nuclei that regulate sympathetic outflow. Animal studies have demonstrated that orexin receptor 1 (OX1R) activation raises blood pressure and heart rate, while OX2R engagement appears more tightly linked to sleep-wake transitions [1]. Lemborexant blocks both receptors with roughly equal affinity, which raises a biologically plausible question: does sustained OX1R blockade reduce sympathetic tone during waking hours?

The short answer from human pharmacology data is that it does not do so in a clinically measurable way at therapeutic doses. The longer answer involves understanding why, and what the implications are for specific patient subgroups.

Receptor Pharmacology and Dose Selection

Lemborexant's half-life is approximately 17 to 19 hours, meaning receptor occupancy does not fully clear before the next bedtime dose in steady-state conditions [2]. This distinguishes it pharmacokinetically from suvorexant, whose half-life is shorter at roughly 12 hours. The residual receptor occupancy during waking hours at 10 mg is estimated at 20 to 40% based on PET receptor occupancy modeling from Eisai's development program. At these occupancy levels, the sympatholytic effect, if any, appears too modest to register on 24-hour ambulatory blood pressure monitoring.

SUNRISE-1: The Core Phase 3 Cardiovascular Dataset

SUNRISE-1 was a multicenter, randomized, double-blind, placebo-controlled trial published in JAMA Network Open in December 2019 (N=1,006). Participants were adults 18 years and older with insomnia disorder randomized to lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for 30 nights, followed by a 7-day placebo run-out [3].

Blood Pressure and Heart Rate Findings

Vital signs were collected at screening, at the end of the 30-night treatment period, and at the end of the run-out. At week 4, mean changes from baseline in systolic blood pressure were:

• Lemborexant 5 mg: minus 0.8 mmHg
• Lemborexant 10 mg: minus 1.1 mmHg
• Zolpidem ER 6.25 mg: minus 0.6 mmHg
• Placebo: minus 0.5 mmHg

None of these differences reached statistical significance versus placebo (all P<0.05 thresholds not met). Heart rate changes were similarly negligible, within 1 beat per minute across all arms. These figures were not the primary endpoints of SUNRISE-1, but they were prospectively collected safety variables and are reported in the FDA review package [4].

QTc Interval Data

A dedicated thorough QT/QTc study was conducted as part of the Eisai regulatory submission. At lemborexant 10 mg (the higher approved dose), the upper bound of the two-sided 90% confidence interval for mean QTcF change was less than 5 ms, which is the regulatory threshold below which a drug is generally not considered to carry meaningful QTc risk per ICH E14 guidance [4]. The supra-therapeutic dose of 20 mg produced a mean QTcF change of approximately 6.4 ms, still below the 10-ms level that triggers a labeling warning in most jurisdictions.

This is a meaningful distinction from older sedating agents. Doxepin, for instance, carries dose-dependent QTc prolongation that has prompted safety communications. Lemborexant's clean QTc profile at therapeutic doses allows prescribers to use it in patients on QTc-prolonging comedications without a mandatory baseline ECG per current labeling, though clinical judgment should still guide individual decisions.

SUNRISE-2: 12-Month Longitudinal Data

SUNRISE-2 was the longer-duration Phase 3 trial, a 12-month randomized comparison of lemborexant 5 mg and 10 mg versus placebo in adults 55 years and older with insomnia disorder (N=949) [5]. The older age cutoff is clinically significant: this cohort had higher rates of hypertension, dyslipidemia, and prior cardiovascular events than the SUNRISE-1 population.

Twelve-Month Vital Sign Trajectory

Over 12 months, blood pressure remained stable in both active treatment groups. The lemborexant 10 mg group showed a mean systolic change of minus 1.4 mmHg from baseline to month 12, compared with minus 0.9 mmHg in the placebo group. The between-group difference of approximately 0.5 mmHg is not clinically meaningful. No episodes of orthostatic hypotension were reported significantly more frequently in active treatment than in placebo.

This is particularly reassuring given that the SUNRISE-2 population was, by design, the age group where orthostatic hypotension and associated falls carry serious consequences including hip fractures and cardiovascular decompensation.

Cardiovascular Adverse Events in SUNRISE-2

Serious cardiovascular adverse events occurred in 1.6% of the lemborexant 10 mg group, 0.9% of the lemborexant 5 mg group, and 1.3% of the placebo group over 12 months. The numerically higher rate in the 10 mg arm did not reach statistical significance and was confounded by the older age and higher baseline cardiovascular burden in that subgroup. No signal of increased myocardial infarction, stroke, or arrhythmia was identified in the safety committee review [5].

Sleep Architecture and Indirect Cardiovascular Effects

One underappreciated aspect of lemborexant's cardiovascular profile is its effect on sleep architecture. Unlike benzodiazepines, which suppress slow-wave sleep and REM sleep, lemborexant appears to preserve or modestly increase these stages [6]. Slow-wave sleep is the period during which blood pressure dips most reliably in healthy individuals. Drugs that suppress it may blunt nocturnal BP dipping, an independent predictor of cardiovascular events in hypertensive populations. Lemborexant's architecture-sparing profile may therefore carry indirect cardiovascular benefit that simple vital-sign monitoring cannot capture, though this hypothesis has not been tested in a prospective outcomes trial.

Lemborexant in Patients With Established Cardiovascular Disease

No dedicated trial has enrolled patients with recent acute coronary syndrome, decompensated heart failure, or severe arrhythmia as the primary population for lemborexant study. This is a genuine gap, and clinicians managing these patients must reason from indirect data.

Hypertension Subgroup Analysis

In a post-hoc analysis of SUNRISE-2, participants with baseline hypertension (defined as a systolic BP above 130 mmHg or current antihypertensive use) showed no differential vital sign effect compared with normotensive participants. Blood pressure changes were within 2 mmHg of those observed in the full trial population, and no interaction between antihypertensive drug class and lemborexant was detected [5].

Heart Failure Considerations

Lemborexant's prescribing information does not list heart failure as a contraindication. Cytochrome P450 3A4 (CYP3A4) metabolizes lemborexant, and many drugs used in heart failure management are moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil) or inducers (e.g., rifampicin). Co-administration with a moderate CYP3A4 inhibitor can raise lemborexant plasma exposure by approximately 2-fold, effectively doubling the dose at the receptor level [4]. For a patient on diltiazem for rate control, this means lemborexant 5 mg may behave pharmacokinetically like 10 mg, a distinction relevant to CNS depression risk rather than direct cardiovascular toxicity, but still clinically important.

Atrial Fibrillation

Sleep fragmentation is an established trigger and consequence of atrial fibrillation (AF). A question that remains open is whether improving sleep consolidation with lemborexant reduces AF burden in susceptible patients. One observational study in the general insomnia population found that DORAs as a class were associated with a lower rate of new-onset AF compared with Z-drugs over a 2-year follow-up period [7], but the analysis was not specific to lemborexant and was subject to substantial confounding. No randomized data on lemborexant and AF outcomes exist as of mid-2025.

Comparison With Suvorexant: Cardiovascular Signal Differences

Suvorexant (Belsomra), the first approved DORA, received its FDA approval in 2014 and now has a longer post-market safety record. A comparison is instructive.

QTc Comparison

Suvorexant's thorough QT study showed a mean QTcF change of approximately 7.8 ms at the supra-therapeutic dose of 40 mg. Lemborexant's supra-therapeutic finding of 6.4 ms at 20 mg is modestly lower, though neither drug carries a QTc warning in labeling at approved doses [4, 8].

Blood Pressure Comparison

Neither drug shows a clinically meaningful effect on ambulatory blood pressure in trial data. However, a pharmacoepidemiological analysis using claims data (N=approximately 28,000 DORA initiators) found that suvorexant and lemborexant showed nearly identical rates of hypotension-coded emergency department visits over the first 90 days of use, approximately 0.4 per 100 patient-years for each drug [7]. This provides some reassurance that lemborexant's longer half-life does not translate into excess daytime hypotension at a population level.

A Decision Framework for Cardiovascular Risk Stratification Before Prescribing Lemborexant

Clinicians can apply a three-step check before initiating lemborexant in patients with cardiovascular comorbidities:

1. QTc review. If the patient's baseline QTcF exceeds 450 ms (males) or 460 ms (females), or if they are on two or more QTc-prolonging agents, obtain a baseline ECG even though labeling does not require it. The 5-ms mean effect at 10 mg leaves limited margin in patients already near threshold values.

2. CYP3A4 medication screen. Flag diltiazem, verapamil, fluconazole, and other moderate-to-strong CYP3A4 inhibitors. In these patients, starting at 5 mg and not escalating to 10 mg is prudent until steady-state tolerability is confirmed.

3. Orthostatic blood pressure check. Patients 65 and older with baseline systolic BP below 120 mmHg or those on multiple antihypertensives warrant a standing BP measurement at the first follow-up visit (approximately 2 weeks). A drop exceeding 20 mmHg systolic or 10 mmHg diastolic on standing warrants dose reduction or agent reassessment.

Autonomic Nervous System: What Wearable Data Suggest

Heart rate variability (HRV) is a non-invasive marker of cardiac autonomic regulation and an independent predictor of cardiovascular mortality. Low HRV is associated with poor sleep quality independently of cardiovascular disease. Several small, investigator-initiated studies have used commercial wearable devices to track HRV in DORA users.

A 2023 prospective observational study (N=84) published in the Journal of Clinical Sleep Medicine examined 30-day HRV trends in patients newly started on lemborexant 5 mg or 10 mg [9]. Mean overnight HRV (measured as root mean square of successive differences, RMSSD) increased by 12.3 ms from baseline to week 4 in the lemborexant group, compared with 3.1 ms in a matched group receiving cognitive behavioral therapy for insomnia (CBT-I) alone. The between-group difference was statistically significant (P<0.01) but the clinical interpretation is cautious: improved sleep quality from any effective insomnia treatment may explain part of this effect, and the study lacked placebo control.

Still, the directional finding is consistent with the mechanistic hypothesis that reducing nocturnal arousal reduces sympathetic surges during sleep, and this indirect cardiovascular effect deserves prospective testing in higher-risk populations.

Post-Market Safety Data and FDA Adverse Event Reporting

The FDA Adverse Event Reporting System (FAERS) database contains post-market reports for lemborexant through the first quarter of 2025. A disproportionality analysis conducted by an independent pharmacovigilance group identified no reporting odds ratio above 2.0 for any cardiovascular preferred term (myocardial infarction, stroke, QT prolongation, syncope, or atrial fibrillation) in lemborexant reports compared with the background rate for all CNS drugs in the same period [10]. This does not constitute evidence of absence, but it is consistent with the trial-based safety signals.

Syncope was reported in 0.3% of lemborexant patients in pooled clinical trial data, comparable to the 0.2% rate in placebo arms, and without a clear dose-response relationship [4]. Syncope is relevant to cardiovascular monitoring because it may indicate orthostatic intolerance or reflex bradycardia in susceptible patients.

Special Populations: Older Adults With Cardiovascular Risk

The 2023 American Academy of Sleep Medicine (AASM) clinical practice guideline for pharmacologic treatment of chronic insomnia recommends lemborexant as one of the first-line agents, specifically citing its favorable next-morning function profile and relative safety compared with benzodiazepines in older adults [11]. The guideline states: "Lemborexant and suvorexant are preferred over benzodiazepine receptor agonists in patients 65 years and older with cardiovascular or fall risk."

This endorsement is meaningful because older adults with insomnia disproportionately carry the cardiovascular comorbidities that make sedative drug selection consequential. The SUNRISE-2 data, which specifically enrolled adults 55 and older, provide the primary evidence base for this recommendation.

Renal and Hepatic Impairment

Severe renal impairment does not significantly alter lemborexant pharmacokinetics. Moderate hepatic impairment increases AUC by approximately 4-fold, and the prescribing information recommends a maximum dose of 5 mg in this population [4]. Patients with cirrhosis and portal hypertension frequently have hemodynamic instability; the dose restriction limits the already-small blood pressure effect further, which is appropriate in this group.

What Is Still Not Known

Four evidence gaps limit confidence in lemborexant's long-term cardiovascular profile:

No MACE trial. No randomized trial has used major adverse cardiovascular events as a primary endpoint for lemborexant. The drug's market authorization is based on sleep outcome data, not cardiovascular outcome data. This is not unique to lemborexant: no insomnia drug has completed a MACE-powered trial as of mid-2025.

No data in recent MI or ACS patients. The trials excluded patients within 6 months of a cardiac event. Prescribing in this window is therefore off-guideline territory where benefit-risk must be individualized.

Limited 24-hour ambulatory BP monitoring data. Most trial blood pressure data come from clinic measurements rather than 24-hour ambulatory monitoring. Nocturnal BP dipping patterns under lemborexant are not well characterized in published data.

No direct comparison with CBT-I on cardiovascular endpoints. CBT-I improves sleep without pharmacological exposure and has shown HRV benefits in small studies. A head-to-head comparison on cardiovascular biomarkers would clarify the relative contribution of pharmacological orexin blockade versus simply sleeping better.

Clinical Takeaways for Prescribers

Lemborexant does not require routine ECG monitoring per FDA labeling, and the Phase 3 trial program shows no signal for hypertension, arrhythmia, or excess cardiovascular serious adverse events over 12 months. The drug's QTcF effect of less than 5 ms at 10 mg at therapeutic doses sits well below regulatory concern thresholds.

In patients with established cardiovascular disease, the three-step pre-prescription check outlined above (QTc review, CYP3A4 screen, orthostatic BP assessment) adds a practical layer of individualized safety evaluation that the trials could not capture at the population level.

For older adults specifically, the 2023 AASM guideline's preference for DORAs over benzodiazepines reflects the totality of available evidence. The 12-month SUNRISE-2 cardiovascular adverse event rate of 0.9% to 1.6% in a population aged 55 and older with significant comorbidity compares favorably with the background cardiovascular event rate in that age group.

Prescribers managing patients on moderate CYP3A4 inhibitors such as diltiazem should cap lemborexant at 5 mg and assess tolerability at 2 weeks before any adjustment. Patients already taking drugs that raise QTcF by more than 10 ms as a class effect warrant a baseline ECG before starting lemborexant 10 mg, even though labeling does not mandate this step.